Owiti, P., et al., Submitted. ISID Grant Report.

Ballif, M., et al., 2022. Disparities in Dolutegravir Uptake Affecting Females of Reproductive Age With HIV in Low-and Middle-Income Countries After Initial Concerns About Teratogenicity An Observational Study.

Undisa, R., et al., 2022. Inflammatory cytokines and cell activation marker in HIV and HIV/TB co-infected patients attending AMPATH clinic at MTRH Eldoret, Kenya. J Clin Images Med Case Rep, 3, p.1559.

Romo, M.L., et al., 2022. Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa. Journal of the International AIDS Society, 25, p.e25961.

Han, W.M., et al., 2021. Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: A multiregional, retrospective cohort study in 31 countries. The Lancet HIV, 8, p.e766–e775.

Romo, M.L., et al., 2021. Viral Load Status Before Switching to Dolutegravir-Containing Antiretroviral Therapy and Associations With Human Immunodeficiency Virus Treatment Outcomes in Sub-Saharan Africa. Clinical Infectious Diseases.

Romo, M.L., et al., 2021. Viral load status before switching to dolutegravir-containing antiretroviral therapy and associations with HIV treatment outcomes in sub-Saharan Africa. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America.

Patsis, I., et al., 2020. Lower rates of ART initiation and decreased retention among ART-na{\"ıve patients who consume alcohol enrolling in HIV care and treatment programs in Kenya and Uganda. PloS one, 15, p.e0240654.

Humphrey, J.M., et al., 2020. Mortality among people with HIV treated for tuberculosis based on positive, negative, or no bacteriologic test results for tuberculosis: the IeDEA Consortium. In Open forum infectious diseases. Oxford University Press US, p. ofaa006.

Bakoyannis, G., et al., 2020. A semiparametric method for the analysis of outcomes during a gap in HIV care under incomplete outcome ascertainment. Statistical communications in infectious diseases, 12.

Masai, J., Diero, L. & Chelagat, D., 2019. Assessment of pre-eclampsia screening services during antenatal care visits at Bungoma County Referral Hospital, Kenya. Kenyan Journal of Nursing & Midwifery, 4, p.1–11.

Zürcher, K., et al., 2019. Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low-and middle-income countries: a multicohort study. Journal of the International AIDS Society, 22, p.e25392.

Pettit, A.C., et al., 2019. Directly observed therapy and risk of unfavourable tuberculosis treatment outcomes among an international cohort of people living with HIV in low-and middle-income countries. Journal of the International AIDS Society, 22, p.e25423.

Zürcher, K., et al., 2019. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. The Lancet Infectious Diseases, 19, p.298–307.

Diero, L., 2019. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multi-centre cohort study.

Humphrey, J.M., et al., 2019. Mortality among adults living with HIV treated for tuberculosis based on positive, negative, or no bacteriologic test results for tuberculosis: the IeDEA consortium. bioRxiv, p.571000.

Rutaihwa, L.K., et al., 2019. Multiple introductions of Mycobacterium tuberculosis lineage 2–Beijing into Africa over centuries. Frontiers in ecology and evolution, 7, p.112.

Zürcher, K., et al., 2018. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries. bioRxiv, p.370056.

Zurcher, K., et al., 2018. Drug susceptibility testing, HIV-coinfection and outcomes in patients treated for tuberculosis in low-and middle-income settings. In JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. JOHN WILEY & SONS LTD THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W …, p. 7–8.

Kantor, R., et al., 2018. HIV second-line failure and drug resistance at high-and low-level viremia in Western Kenya. AIDS (London, England), 32, p.2485.

Holmes, C.B., et al., 2018. Increased prevalence of pregnancy and comparative risk of program attrition among individuals starting HIV treatment in East Africa. PloS one, 13, p.e0190828.

Bershetyn, A., et al., 2017. The causal effect of tracing by peer health workers on return to clinic among patients who were lost to follow-up from antiretroviral therapy in Eastern Africa: a “natural experiment” arising from surveillance of lost patients. Clinical Infectious Diseases, 64, p.1547–1554.

Simiyu, B.W., et al., 2017. Ccr5 co-receptor expression on circulating cd4+ lymphocytes in hiv-1 patients on haart at moi teaching and referral hospital, eldoret-Kenya.

Coetzer, M., et al., 2017. Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya. Journal of the international AIDS Society, 20, p.e25024.

Diero, L., Kemboi, E. & Orido, M., 2017. Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya.